Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Novartis -- Ignore unavailable to you. Want to Upgrade?

To: Chuck. Edwards who wrote (161)	1/31/1998 10:43:00 AM
From: AMF	Respond to of 296

Chuck and Paul: You're right. I'm wrong. Thanks for setting me straight.

To: Chuck. Edwards who wrote (161)	1/31/1998 10:48:00 AM
From: Chuck. Edwards	Read Replies (1) \| Respond to of 296

By the way, AMF, according to Zack's, Novartis is trading at 25 times "this year's" earnings (I take this to mean the just-completed year, whose earnings will be reported in March). It is trading at less than 22 times next year's projected earnings. Year-over-year growth is projected to be 16 percent. In contrast, companies like Schering-Plough and Pfizer are trading at around 40 times trailing earnings, or a 60 percent premium to Novartis. They may have somewhat higher growth rates than Novartis (Schering-Plough is growing at around 20 percent, I don't know Pfizer's rate), but you are paying a rich price for it. I am comfortable owning Novartis. Good investing Chuck Edwards